368 related articles for article (PubMed ID: 34227881)
1. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery.
Kang HJ; Kim H; Lee DH; Hur BY; Hwang YJ; Suh KS; Han JK
Radiology; 2021 Sep; 300(3):572-582. PubMed ID: 34227881
[TBL] [Abstract][Full Text] [Related]
2. Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma.
Mulé S; Galletto Pregliasco A; Tenenhaus A; Kharrat R; Amaddeo G; Baranes L; Laurent A; Regnault H; Sommacale D; Djabbari M; Pigneur F; Tacher V; Kobeiter H; Calderaro J; Luciani A
Radiology; 2020 Jun; 295(3):562-571. PubMed ID: 32228294
[TBL] [Abstract][Full Text] [Related]
3. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
[TBL] [Abstract][Full Text] [Related]
4. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
[TBL] [Abstract][Full Text] [Related]
5. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
[TBL] [Abstract][Full Text] [Related]
6. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
Kim SS; Lee S; Kim MJ
Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
[TBL] [Abstract][Full Text] [Related]
8. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
9. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
Rhee H; Cho ES; Nahm JH; Jang M; Chung YE; Baek SE; Lee S; Kim MJ; Park MS; Han DH; Choi JY; Park YN
J Hepatol; 2021 Jan; 74(1):109-121. PubMed ID: 32818570
[TBL] [Abstract][Full Text] [Related]
10. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and Prognostication of Gd-EOB-DTPA MRI and CT in Patients With Macrotrabecular-Massive Hepatocellular Carcinoma.
Cheng J; Li X; Wang L; Chen F; Li Y; Zuo G; Pei M; Zhang H; Yu L; Liu C; Wang J; Han Q; Cai P; Li X
J Magn Reson Imaging; 2024 Jun; 59(6):2071-2081. PubMed ID: 37840197
[TBL] [Abstract][Full Text] [Related]
12. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary versus Extracellular MRI Contrast Agents in Hepatocellular Carcinoma Detection: Hepatobiliary Phase Features in Relation to Disease-free Survival.
Kim DK; An C; Chung YE; Choi JY; Lim JS; Park MS; Kim MJ
Radiology; 2019 Dec; 293(3):594-604. PubMed ID: 31592730
[TBL] [Abstract][Full Text] [Related]
14. Prognostic MRI features to predict postresection survivals for very early to intermediate stage hepatocellular carcinoma.
Jiang H; Qin Y; Wei H; Zheng T; Yang T; Wu Y; Ding C; Chernyak V; Ronot M; Fowler KJ; Chen W; Bashir MR; Song B
Eur Radiol; 2024 May; 34(5):3163-3182. PubMed ID: 37870624
[TBL] [Abstract][Full Text] [Related]
15. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.
Choi JY; Kim MJ; Park YN; Lee JM; Yoo SK; Rha SY; Seok JY
AJR Am J Roentgenol; 2011 Aug; 197(2):399-405. PubMed ID: 21785086
[TBL] [Abstract][Full Text] [Related]
17. Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis.
Kang TW; Kong SY; Kang D; Kang MW; Kim YK; Kim SH; Sinn DH; Kim YA; Choi KS; Lee ES; Woo SM; Back JH; Guallar E; Cho J
Radiology; 2020 Apr; 295(1):114-124. PubMed ID: 32013789
[TBL] [Abstract][Full Text] [Related]
18. Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma.
Iwamoto T; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Ohashi H; Fujita N; Kudo M; Takehara T
Dig Dis; 2017; 35(6):574-582. PubMed ID: 29040990
[TBL] [Abstract][Full Text] [Related]
19. Prediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.
Lu M; Qu Q; Xu L; Zhang J; Liu M; Jiang J; Shen W; Zhang T; Zhang X
Acad Radiol; 2023 May; 30(5):841-852. PubMed ID: 36577606
[TBL] [Abstract][Full Text] [Related]
20. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
